De-escalation of antimicrobial therapy for bacteraemia due to difficult-to-treat Gram-negative bacilli

Infection

Volumn 41, Issue 1, 2013, Pages 203-210

  Shime, N ^a,b   Kosaka, T ^b   Fujita, N ^b  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antimicrobial de escalation; Bacteraemia; Drug resistance; Empiric antimicrobial therapy; Gram negative bacilli

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIINFECTIVE AGENT; BIAPENEM; CEFAZOLIN; CEFEPIME; CEFMETAZOLE; CEFOTAXIME; CEFOTIAM; CEFOZOPRAN; CEFPIROME; CEFTAZIDIME; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; DORIPENEM; FLOMOXEF; GENTAMICIN; LEVOFLOXACIN; MEROPENEM; PANIPENEM PLUS BETAMIPRON; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; POLYPEPTIDE ANTIBIOTIC AGENT; SULPERAZON; SULTAMICILLIN; TEICOPLANIN; UNINDEXED DRUG;

ACINETOBACTER; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ANTIMICROBIAL THERAPY DE ESCALATION; ARTICLE; BACTEREMIA; BLOOD CULTURE; CITROBACTER; DEATH; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ENTEROBACTER; FEMALE; GRAM NEGATIVE BACTERIUM; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTCOME ASSESSMENT; PRESCRIPTION; PSEUDOMONAS; RECURRENT INFECTION; SERRATIA;

AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84873742512     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-012-0388-5     Document Type: Article

References (30)

1. Leibovici L, Drucker M, Konigsberger H, Samra Z, Harrari S, Ashkenazi S, Pitlik SD. Septic shock in bacteremic patients: risk factors, features and prognosis. Scand J Infect Dis. 1997;29:71-5.
2. Byl B, Clevenbergh P, Jacobs F, Struelens MJ, Zech F, Kentos A, Thys JP. Impact of infectious diseases specialists and microbiological data on the appropriateness of antimicrobial therapy for bacteremia. Clin Infect Dis. 1999;29:60-6.
3. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest. 2000;118:146-55.
4. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med. 2003;115:529-35.
5. Sostarich AM, Zolldann D, Haefner H, Luetticken R, Schulze-Roebecke R, Lemmen SW. Impact of multiresistance of gram-negative bacteria in bloodstream infection on mortality rates and length of stay. Infection. 2008;36:31-5.
6. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL; International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine; European Respiratory Society; International Sepsis Forum; Japanese Association for Acute Medicine; Japanese Society of Intensive Care Medicine; Society of Critical Care Medicine; Society of Hospital Medicine; Surgical Infection Society; World Federation of Societies of Intensive and Critical Care Medicine. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36:296-327.
7. Depuydt PO, Blot SI, Benoit DD, Claeys GW, Verschraegen GL, Vandewoude KH, Vogelaers DP, Decruyenaere JM, Colardyn FA. Antimicrobial resistance in nosocomial bloodstream infection associated with pneumonia and the value of systematic surveillance cultures in an adult intensive care unit. Crit Care Med. 2006;34:653-9.
8. Patterson JE. Multidrug-resistant gram-negative pathogens: multiple approaches and measures for prevention. Infect Control Hosp Epidemiol. 2006;27:889-92.
9. Michalopoulos A, Falagas ME. Treatment of Acinetobacter infections. Expert Opin Pharmacother. 2010;11:779-88.
10. Joo EJ, Kang CI, Ha YE, Park SY, Kang SJ, Wi YM, Lee NY, Chung DR, Peck KR, Song JH. Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: a stratified analysis according to sites of infection. Infection. 2011;39:309-18.
11. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother. 2005;49:760-6.
12. Jones RN. Important and emerging beta-lactamase-mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol Infect Dis. 1998;31:461-6.
13. Clinical and Laboratory Standards Institute (CLSI). Analysis and presentation of cumulative antimicrobial susceptibility test data. 2nd ed. Approved guideline M39-A2. Wayne, PA: CLSI. 2006.
14. Kollef MH, Morrow LE, Niederman MS, Leeper KV, Anzueto A, Benz-Scott L, Rodino FJ. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest. 2006;129:1210-8.
15. McCabe WR, Jackson GG. Gram-negative bacteremia. I. Etiology and ecology. Arch Intern Med. 1962;110:847-55.
16. Kuti EL, Patel AA, Coleman CI. Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-associated pneumonia and blood stream infection: a meta-analysis. J Crit Care. 2008;23:91-100.
17. Dellit TH, Chan JD, Skerrett SJ, Nathens AB. Development of a guideline for the management of ventilator-associated pneumonia based on local microbiologic findings and impact of the guideline on antimicrobial use practices. Infect Control Hosp Epidemiol. 2008;29:525-33.
18. Patterson JE. Antibiotic utilization: is there an effect on antimicrobial resistance? Chest. 2001;119:426S-30S.
19. Willemsen I, Bogaers-Hofman D, Winters M, Kluytmans J. Correlation between antibiotic use and resistance in a hospital: temporary and ward-specific observations. Infection. 2009;37:432-7.
20. Shime N, Satake S, Fujita N. De-escalation of antimicrobials in the treatment of bacteraemia due to antibiotic-sensitive pathogens in immunocompetent patients. Infection. 2011;39:319-25.
21. Giantsou E, Liratzopoulos N, Efraimidou E, Panopoulou M, Alepopoulou E, Kartali-Ktenidou S, Manolas K. De-escalation therapy rates are significantly higher by bronchoalveolar lavage than by tracheal aspirate. Intensive Care Med. 2007;33:1533-40.
22. De Waele JJ, Ravyts M, Depuydt P, Blot SI, Decruyenaere J, Vogelaers D. De-escalation after empirical meropenem treatment in the intensive care unit: fiction or reality? J Crit Care. 2010;25:641-6.
23. Rolston KV, Mahajan SN, Chemaly RF. Antimicrobial de-escalation in cancer patients. Infection. 2012;40:223-4.
24. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ. 2004;328:668.
25. Garnacho-Montero J, Sa-Borges M, Sole-Violan J, Barcenilla F, Escoresca-Ortega A, Ochoa M, Cayuela A, Rello J. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med. 2007;35:1888-95.
26. Eachempati SR, Hydo LJ, Shou J, Barie PS. Does de-escalation of antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients? J Trauma. 2009;66:1343-8.
27. Deresinski S. Principles of antibiotic therapy in severe infections: optimizing the therapeutic approach by use of laboratory and clinical data. Clin Infect Dis. 2007;45 Suppl 3:S177-83.
28. Pea F, Viale P. Bench-to-bedside review: appropriate antibiotic therapy in severe sepsis and septic shock - does the dose matter? Crit Care. 2009;13:214.
29. Dunne WM Jr, Hardin DJ. Use of several inducer and substrate antibiotic combinations in a disk approximation assay format to screen for AmpC induction in patient isolates of Pseudomonas aeruginosa, Enterobacter spp., Citrobacter spp., and Serratia spp. J Clin Microbiol. 2005;43:5945-9.
30. Deal EN, Micek ST, Reichley RM, Ritchie DJ. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study. Clin Ther. 2009;31:299-310.